Recognition of Borderline Resectable Colorectal Liver Metastases as a Distinct Entity

The review delineates ‘borderline resectable colorectal liver metastases’ (BR-CRLM) as a distinct category, integrating both surgical and oncological criteria for optimal decision-making. Current treatments highlight the necessity of pre-operative chemotherapy and advanced surgical interventions, which now offer substantial long-term survival benefits. By emphasizing this classification, clinicians can better tailor therapeutic strategies, involving locoregional therapies and targeted approaches, enhancing outcomes for patients who previously faced limited options.